1 completed, 1 withdrawn. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
Follow Asahi Kasei Pharma America Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy ART-123, Placebo Comparator - Placebo - Sepsis and Coagulopathy | Phase 3 | Withdrawn | Asahi Kasei Pharma America Corporation | 2019-07-01 | 2019-09-13 | |
| Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy ART-123, Placebo - Severe Sepsis, Coagulopathy | Phase 3 | Completed | Asahi Kasei Pharma America Corporation | 816 | 2012-10-29 | 2020-04-21 |
Hemostatic Disorders (2) · Sepsis (2)
ART123 (2)
Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Croatia (1) · Czechia (1) · Finland (1) · France (1) · Germany (1) · Hungary (1) · India (1) · Israel (1) · Netherlands (1)
David Fineberg, M.D. (1) · David Fineberg, MD (1)